NovoCure Limited
NovoCure Limited (NVCR) Revenue
Annual & quarterly revenue history · segment & region breakdown
NVCR · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsNovoCure Limited trailing twelve-month (TTM) revenue is $0.67B, an increase of 8.28% year-over-year from $0.66B in FY2025.
Revenue trend
2025 – 2013 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.66B | +$0.05B | +8.28% |
| 2024-12-31 | $0.61B | +$0.10B | +18.82% |
| 2023-12-31 | $0.51B | -$0.03B | -5.30% |
| 2022-12-31 | $0.54B | +$0.00B | +0.53% |
| 2021-12-31 | $0.54B | +$0.04B | +8.23% |
| 2020-12-31 | $0.49B | +$0.14B | +40.72% |
| 2019-12-31 | $0.35B | +$0.10B | +41.62% |
| 2018-12-31 | $0.25B | +$0.07B | +40.13% |
| 2017-12-31 | $0.18B | +$0.09B | +113.57% |
| 2016-12-31 | $0.08B | +$0.05B | +150.52% |
Compare revenue vs peers
Medical - Instruments & SuppliesCompare NVCR revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income NovoCure Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
NovoCure Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from NovoCure Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
NVCR revenue · 5 questionsNVCR's trailing twelve-month (TTM) revenue is $0.67B. That is an increase of 8.28% year-over-year from $0.66B in FY2025.
▸ Source: FMP · NovoCure Limited SEC filings · GAAP · NovoCure Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026